Targeting inflammatory pathways in chronic lymphocytic leukemia.
Targeting inflammatory pathways in chronic lymphocytic leukemia.
复制标题
DOI：
10.1016/j.critrevonc.2013.07.011
复制
发表时间：
2013-12
影响因子：
6.2
通讯作者：
Estrov, Zeev
中科院分区：
文献类型：
--
作者：
Rozovski, Uri;Keating, Michael J.;Estrov, Zeev
尽管最近在白血病研究方面取得了重大进展，但慢性淋巴细胞白血病（CLL）的病理生物学仍然知之甚少。本文就慢性炎症在慢性淋巴细胞白血病发生发展中的作用作一综述。炎性细胞因子和趋化因子的强烈产生伴随着细胞内促炎通路的激活，以及激活促炎信号传导通路的体细胞突变的存在，表明慢性炎症在这种疾病中起着病理生理作用。事实上，糖皮质激素和非甾体抗炎药具有抗肿瘤活性，糖皮质激素已被广泛用于治疗CLL及其并发症。最近的临床试验表明，酪氨酸激酶抑制剂，如伊曲替尼和免疫调节剂来那度胺，在复发或难治性疾病的CLL患者中诱导了令人印象深刻的临床反应。由于这些促炎途径抑制剂和免疫调节药物被证明在CLL中有效，因此目前正在临床试验中研究具有类似活性的其他药物。对CLL病理生物学的新见解和新型药物的开发无疑将为我们提供治疗甚至治愈CLL的有效工具。
Despite recent major advances in leukemia research, the pathobiology of chronic lymphocytic leukemia (CLL) remains poorly understood. Herein we review the role chronic inflammation plays in the initiation and progression of CLL. The robust production of inflammatory cytokines and chemokines accompanied by activation of intra-cellular pro-inflammatory pathways, and the presence of somatic mutations that activate pro-inflammatory signaling pathways, suggest that chronic inflammation plays a pathophysiological role in this disease. Indeed, glucocorticoids and non-steroidal anti-inflammatory possess anti-tumor activity, and glucocorticoids have been broadly used to treat CLL and its complications. Recent clinical trials demonstrated that tyrosine kinase inhibitors, such as ibrutinib and the immune-modulatory agent lenalidomide, induced impressive clinical responses in CLL patients with relapsed or refractory disease. As those pro-inflammatory pathway inhibitors and immune modulating drugs proved to be effective in CLL, other agents with similar activities are currently investigated in clinical trials. New insights into the pathobiology of CLL and the development of novel classes of drugs will undoubtedly provide us with effective tools to treat and perhaps cure CLL.
登录
查看更多内容
DOI：
10.1158/1078-0432.ccr-10-2879
发表时间：
2011-05-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Amrein PC;Attar EC;Takvorian T;Hochberg EP;Ballen KK;Leahy KM;Fisher DC;Lacasce AS;Jacobsen ED;Armand P;Hasserjian RP;Werner L;Neuberg D;Brown JR
通讯作者：
Brown JR
影响因子：
82.9
作者：
Cantwell, M;Hua, T;Kipps, TJ
通讯作者：
Kipps, TJ
影响因子：
45.3
作者：
Chen, Christine I.;Bergsagel, P. Leif;Trudel, Suzanne
通讯作者：
Trudel, Suzanne
DOI：
10.1016/s0190-9622(98)70398-6
发表时间：
1998-07-01
影响因子：
13.8
作者：
Davis, MDP;Perniciaro, C;Leiferman, KM
通讯作者：
Leiferman, KM
影响因子：
20.3
作者：
Del Giudice, Ilaria;Chiaretti, Sabina;Foa, Robin
通讯作者：
Foa, Robin